🇺🇸 FDA
Pipeline program

Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

VGFT-OD-1009

Phase 3 small_molecule completed

Quick answer

Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) for Diabetic Macular Edema is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Diabetic Macular Edema
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials